Sun Pharmaceutical Industries Ltd

Sun Pharma.Inds. Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Sun Pharmaceutical Industries Ltd

₹ 1,690 -0.28%
10 Jun 2:00 p.m.
sunpharma.com BSE: 524715 NSE: SUNPHARMA
About

Sun Pharmaceutical Industries Ltd is engaged in the business of manufacturing, developing and marketing a wide range of branded and generic formulations and Active Pharma Ingredients (APIs). The company and its subsidiaries has various manufacturing facilities spread across the world with trading and other incidental and related activities extending to global market.[1] It is the largest pharmaceutical company in India.[2]

Key Points

Product Offerings
The company produces a range of generic and specialty medications for chronic and acute conditions. Its product portfolio includes generics, branded generics, specialty pharmaceuticals, advanced technology-based products, antiretrovirals, active pharmaceutical ingredients (APIs), and intermediates. It offers medications in multiple dosage forms, such as injectables, sprays, ointments, creams, liquids, tablets, and capsules. [1] [2]The company offers 26+ products in the global specialty market, with a strategic focus on dermatology, ophthalmology, and onco-dermatology segments. [3]

Website BSE NSE
  • Market Cap ₹ 4,05,380 Cr.
  • Current Price ₹ 1,690
  • High / Low ₹ 1,960 / 1,461
  • Stock P/E 35.4
  • Book Value ₹ 301
  • Dividend Yield 0.94 %
  • ROCE 20.2 %
  • ROE 16.9 %
  • Face Value ₹ 1.00
Edit ratios

Pros

  • Company has reduced debt.
  • Company is almost debt free.
  • Company has delivered good profit growth of 23.8% CAGR over last 5 years
  • Company has been maintaining a healthy dividend payout of 33.8%

Cons

  • The company has delivered a poor sales growth of 9.87% over past five years.
  • Working capital days have increased from 115 days to 174 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE Sensex Nifty 50 BSE 500 BSE Healthcare BSE 100

Edit Columns
Loading peers table ...

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

Mar 2022 Jun 2022 Sep 2022 Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
9,447 10,762 10,952 11,241 10,931 11,941 12,192 12,381 11,983 12,653 13,291 13,675 12,959
7,106 7,877 7,996 8,237 8,129 8,609 9,013 8,904 8,948 9,045 9,352 9,666 9,243
Operating Profit 2,340 2,884 2,957 3,004 2,802 3,332 3,179 3,477 3,035 3,608 3,939 4,009 3,716
OPM % 25% 27% 27% 27% 26% 28% 26% 28% 25% 29% 30% 29% 29%
-3,822 2 85 174 202 -118 294 180 504 533 354 149 251
Interest 37 14 19 46 93 81 49 35 74 62 69 52 49
Depreciation 556 588 610 660 672 651 633 622 650 655 626 631 664
Profit before tax -2,076 2,285 2,412 2,471 2,240 2,481 2,791 3,000 2,816 3,424 3,598 3,476 3,254
Tax % 7% 8% 6% 11% 10% 19% 14% 14% 5% 16% 16% 16% 34%
-2,227 2,093 2,256 2,181 1,983 2,006 2,385 2,561 2,659 2,861 3,037 2,913 2,154
EPS in Rs -9.49 8.59 9.43 9.03 8.27 8.43 9.90 10.52 11.06 11.82 12.67 12.10 8.96
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
16,080 27,392 28,487 31,578 26,489 29,066 32,838 33,498 38,654 43,886 48,497 52,578
9,078 19,498 20,313 21,476 20,858 22,689 25,855 25,028 28,397 32,235 35,479 37,307
Operating Profit 7,003 7,894 8,174 10,102 5,631 6,377 6,983 8,470 10,258 11,650 13,018 15,272
OPM % 44% 29% 29% 32% 21% 22% 21% 25% 27% 27% 27% 29%
-1,968 283 -42 610 -135 -258 382 -3,449 -3,505 459 865 1,287
Interest 44 579 523 400 518 555 303 141 127 172 238 231
Depreciation 409 1,195 1,038 1,265 1,500 1,753 2,053 2,080 2,144 2,529 2,557 2,575
Profit before tax 4,581 6,403 6,571 9,048 3,479 3,810 5,010 2,799 4,481 9,408 11,088 13,752
Tax % 15% 14% 14% 13% 26% 16% 16% 18% 24% 9% 13% 20%
3,879 5,476 5,658 7,846 2,542 3,208 4,172 2,272 3,389 8,513 9,610 10,965
EPS in Rs 15.17 21.92 18.89 29.03 8.73 11.11 15.69 12.10 13.64 35.32 39.91 45.55
Dividend Payout % 10% 14% 5% 12% 23% 25% 25% 62% 73% 33% 34% 35%
Compounded Sales Growth
10 Years: 7%
5 Years: 10%
3 Years: 11%
TTM: 8%
Compounded Profit Growth
10 Years: 10%
5 Years: 24%
3 Years: 20%
TTM: 15%
Stock Price CAGR
10 Years: 8%
5 Years: 29%
3 Years: 26%
1 Year: 12%
Return on Equity
10 Years: 14%
5 Years: 15%
3 Years: 17%
Last Year: 17%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 207 207 241 240 240 240 240 240 240 240 240 240
Reserves 18,318 25,431 32,742 36,400 38,074 41,169 45,025 46,223 47,771 55,755 63,427 71,978
2,561 8,996 8,497 9,832 10,385 10,514 8,315 3,869 1,290 6,886 3,274 2,362
8,009 14,089 13,948 14,624 15,598 12,666 14,615 17,291 20,474 17,831 18,367 17,520
Total Liabilities 29,095 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,308 92,101
6,817 12,682 15,872 17,675 18,853 21,837 22,847 21,553 22,665 24,065 23,211 27,996
CWIP 842 2,039 2,175 2,801 2,465 1,411 1,220 1,567 1,287 4,973 5,354 1,234
Investments 2,786 2,716 1,830 1,192 7,143 7,903 10,143 9,612 12,849 14,824 15,026 18,354
18,650 31,286 35,550 39,427 35,837 33,439 33,984 34,890 32,975 36,849 41,717 44,517
Total Assets 29,095 48,723 55,428 61,095 64,297 64,590 68,194 67,622 69,776 80,712 85,308 92,101

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
3,959 5,616 6,686 7,082 3,907 2,196 6,555 6,170 8,985 4,959 12,135 14,072
-2,176 -1,502 -3,949 -4,186 -3,104 -310 -2,225 407 -5,556 -7,220 -763 -5,306
507 -1,187 -1,889 -2,285 -1,539 -2,731 -5,715 -5,980 -5,193 2,376 -6,710 -7,906
Net Cash Flow 2,290 2,927 848 611 -736 -844 -1,386 596 -1,765 115 4,662 860

Ratios

Consolidated Figures in Rs. Crores / View Standalone

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 50 68 87 83 108 112 105 99 99 95 85 91
Inventory Days 410 307 370 307 338 366 311 378 315 360 338 348
Days Payable 174 178 207 197 234 192 142 167 158 194 194 210
Cash Conversion Cycle 286 197 251 193 212 285 274 310 255 261 229 228
Working Capital Days 126 76 104 73 79 137 112 84 55 93 78 174
ROCE % 34% 23% 18% 20% 10% 10% 10% 13% 17% 16% 17% 20%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48% 54.48%
14.95% 16.00% 16.87% 16.88% 16.48% 16.78% 17.08% 17.72% 17.23% 18.01% 18.04% 17.96%
19.66% 19.64% 19.08% 19.18% 19.65% 19.56% 19.42% 18.71% 19.17% 18.48% 18.43% 18.58%
0.00% 0.06% 0.06% 0.06% 0.09% 0.10% 0.11% 0.11% 0.11% 0.11% 0.11% 0.11%
10.91% 9.80% 9.52% 9.38% 9.28% 9.05% 8.92% 8.97% 9.00% 8.89% 8.92% 8.86%
No. of Shareholders 6,47,1676,43,5126,32,3376,25,2526,24,5616,16,5886,12,6266,31,3926,73,2176,57,3176,89,6237,04,983

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

Credit ratings

Concalls